You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Introduction

Worldwide prevalence rates for type 2 diabetes mellitus (T2DM) vary considerably. The prevalence of T2DM in Europe is expected to increase 20% within the next 20 years. Effective management of diabetes is a dynamic and individualized process, requiring an appropriate treatment regimen and long-term monitoring. New classes of antihyperglycemic agents are being developed which may help further individualize care with the goal of achieving glycemic control in T2DM.

Activities

Local Perspectives

France
Germany
Portugal
Spain

Steering Committee

Steering Committee Chair
  • Tina Vilsbøll, MD, DMScTina Vilsbøll, MD, DMSc
    Head of Diabetes Research
    Gentofte Hospital
    University of Copenhagen
    Copenhagen, Denmark

Steering Committee Members
  • Michael A. Nauck, MD, PhDMichael A. Nauck, MD, PhD
    Professor of Internal Medicine; Head, Specialist Centre for Diabetes and Metabolic Diseases, Diabetes Centre, Bad Lauterberg, Germany
  • Johan Jendle, MD, PhDJohan Jendle, MD, PhD
    Associate Professor, Endocrine and Diabetes Center, Karlstad Hospital, Sweden
  • Eduard Montanya, MD, PhDEduard Montanya, MD, PhD
    Professor, Department of Clinical Sciences, University of Barcelona; Chief, Department of Diabetes, Bellvitge University Hospital, Barcelona, Spain
  • Jack Leahy, MDJack Leahy, MD
    Professor of Medicine; Chief of Endocrinology, Diabetes, and Metabolism Unit, University of Vermont College of Medicine, Burlington, Vermont, USA
  • John Petrie, MD, PhDJohn Petrie, MD, PhD
    Professor of Diabetic Medicine, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
  • Jiten Vora, MDSebastiano Filetti, MD
    Department of Clinical Sciences, University of Rome "La Sapienza", Rome, Italy
  • Disclaimer: This Clinical Advances is intended for an audience of healthcare professionals located outside the United States.
    Supported by an independent educational grant from
    Novo Nordisk Global

    Polling Questions


    With pending approval of multiple once-weekly GLP-1 RAs for T2DM, in which patients do you believe they will be primarily used?
    In patients already on insulin
    In patients who are at high risk for hypoglycemia
    In patients with moderate renal impairment
    In patients already on a GLP-1 RA
    In patients who do not reach their HbA1c goal on oral therapy

    Related Resources

    Downloadable Slide Kit
    Clinical Articles
    Related Links

    Disclosures

    Steering Committee
    Tina Vilsbøll, MD, DMSc

    Tina Vilsbøll, MD, DMSc, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk
    Received grants for clinical research from: Merck Sharp & Dohme Corp.; Novo Nordisk

    Sebastiano Filetti, MD

    Sebastiano Filetti, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Novo Nordisk
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Novo Nordisk
    Received grants for clinical research from: Eli Lilly and Company

    Johan H. Jendle, MD, PhD

    Johan H. Jendle, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Medtronic, Inc.; Novo Nordisk; Pfizer Inc.
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk; Pfizer Inc.

    Jack L. Leahy, MD,

    Jack L. Leahy, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Janssen Global Services LLC; Merck & Co., Inc.; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.
    Served as a speaker or a member of a speakers bureau for: sanofi-aventis
    Received grants for clinical research from: Takeda Pharmaceuticals North America, Inc.

    Eduard Montanya, MD, PhD

    Eduard Montanya, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Intarcia Therapeutics, Inc.; Novo Nordisk
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk
    Spouse owns stock, stock options, or bonds from: Almirall Prodesfarma, S.A.

    Michael A. Nauck, MD, PhD

    Michael A. Nauck, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; MannKind Corporation; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
    Served as a speaker or a member of a speakers bureau for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; MannKind Corporation; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Merck Sharp & Dohme Corp.; MetaCure Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Tolerx, Inc.

    John R. Petrie, MD, PhDL

    John R. Petrie, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novo Nordisk; Roche; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.
    Served as a speaker or a member of a speakers bureau for: GlaxoSmithKline; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
    Received grants for clinical research from: JDRF; Merck Serono
    Has a research agreement with: Itamar Medical